[HTML][HTML] Mechanistic considerations for the use of monoclonal antibodies for cancer therapy
PM Glassman, JP Balthasar - Cancer biology & medicine, 2014 - ncbi.nlm.nih.gov
Since the approval of rituximab in 1997, monoclonal antibodies (mAbs) have become an
increasingly important component of therapeutic regimens in oncology. The success of …
increasingly important component of therapeutic regimens in oncology. The success of …
[HTML][HTML] Combination radioimmunotherapy strategies for solid tumors
Combination radioimmunotherapy is an emerging approach for the treatment of solid tumors
where radio immunotherapy alone has proven to be reasonably ineffective …
where radio immunotherapy alone has proven to be reasonably ineffective …
Prospective evaluation of cetuximab-mediated antibody-dependent cell cytotoxicity in metastatic colorectal cancer patients predicts treatment efficacy
AM Trotta, A Ottaiano, C Romano, G Nasti… - Cancer immunology …, 2016 - AACR
Cetuximab is a monoclonal antibody to the EGFR that induces antibody-dependent cell
cytotoxicity (ADCC) through Fcγ receptors on immune cells. Although SNPs in genes …
cytotoxicity (ADCC) through Fcγ receptors on immune cells. Although SNPs in genes …
A cetuximab-mediated suicide system in chimeric antigen receptor–modified hematopoietic stem cells for cancer therapy
Using gene modification of hematopoietic stem cells (HSC) to create persistent generation of
multilineage immune effectors to target cancer cells directly is proposed. Gene-modified …
multilineage immune effectors to target cancer cells directly is proposed. Gene-modified …
Study protocol: phase II study to evaluate the effect of cetuximab monotherapy after immunotherapy with PD-1 inhibitors in patients with head and neck squamous cell …
KM Burcher, CH Bloomer, E Gavrila… - Therapeutic …, 2024 - journals.sagepub.com
Background: Immunotherapy with programmed death receptor-1 (PD-1) inhibitors, as a
single agent or in combination with chemotherapy, is the standard first-line treatment for …
single agent or in combination with chemotherapy, is the standard first-line treatment for …
[HTML][HTML] Peripheral white blood cell subsets in metastatic colorectal cancer patients treated with cetuximab: the potential clinical relevance
IZ Matić, B Kolundžija, A Damjanović, J Spasić… - Frontiers in …, 2018 - frontiersin.org
It was demonstrated that cetuximab-induced tumor regression is based on the effects
exerted by immune cells included mainly in the innate immune response. Therefore, the …
exerted by immune cells included mainly in the innate immune response. Therefore, the …
Relación entre la expresión proteínas inhibidoras de complemento y la eficacia de anticuerpos terapéuticos en cáncer colorrectal
SÁ Lorenzo, NS Jazmín - Revista de Farmacología, 2022 - revistafarmacologia.mx
El cáncer colorrectal ocupa el segundo lugar en mortalidad a nivel nacional y el tercero en
incidencia a nivel mundial. Su tratamiento involucra cirugía, radioterapia y combinaciones …
incidencia a nivel mundial. Su tratamiento involucra cirugía, radioterapia y combinaciones …
Machbarkeit und Sicherheit einer kombinierten Therapie mittels transarterieller Chemoembolisation mit Irinotecan beladenen Mikrosphären (DEBIRI-TACE) und CT …
MA Meddeb - 2022 - refubium.fu-berlin.de
Das kolorektale Karzinom ist die dritthäufigste maligne Erkrankung weltweit und die
Inzidenz zeigt eine steigende Tendenz. Hepatisch metastasierte kolorektale Karzinome …
Inzidenz zeigt eine steigende Tendenz. Hepatisch metastasierte kolorektale Karzinome …
Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
N Suzuki - US Patent 11,612,653, 2023 - Google Patents
US11612653B2 - Anti-tumor agent containing immunomodulator, and antitumor effect
potentiator - Google Patents US11612653B2 - Anti-tumor agent containing …
potentiator - Google Patents US11612653B2 - Anti-tumor agent containing …
[PDF][PDF] Targeting p53 in anticancer therapy: Searching for new small molecule activators.
BS da Silva - 2018 - repositorio-aberto.up.pt
This work was performed at the Laboratory of Microbiology of Biological Sciences
Department of Faculty of Pharmacy of University of Porto, in collaboration with Laboratory of …
Department of Faculty of Pharmacy of University of Porto, in collaboration with Laboratory of …